Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer

By sjmartinez • March 16, 2024

Nickols NG, Tsai S, Kane N, Tran S, Ghayouri L, Diaz-Perez S, Thein M, Anderson-Berman N, Eason J, Kishan AU, Steinberg ML, Reiter RE, Lee SP, Gin GE, Kwon R, Chang MG, Chao HH, Solanki AA, Sexton R, Lewis M, Lorentz W, Cheung MK, Gage DL, Duriseti S, Valle L, Berenji G, Aronson WJ, Garraway IP, Rettig MB. Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer. Eur Urol. 2024 Mar 14:S0302-2838(24)00079-4. doi: 10.1016/j.eururo.2024.02.008. Epub ahead of print. PMID: 38490853.

Tags: Hematology/Oncology, Publications, Veterans Administration

Related Posts

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial

Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG,[...]

Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results

Deng J, Pal A, Testa S, Xu JW, Tran LM, Graham DS, Hargil A, Subramanian A, Campbell KM, Limsuwannarot S, Chumpitaz Lavalle Á, Chin SC,[...]

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD

Riess JW, Yu HA, Le X, de Langen AJ, Cho BC, Piotrowska Z, Hendriks LEL, Morabito A, Bonanno L, Brustugun OT, Halvorsen TO, Kim YJ,[...]